← Who reports today · Health Care
How Elevance Health (ELV) makes money: Q3 2026 revenue breakdown
Shareholders' net income
$1,365M
up 14.8% y/y
Total revenues
$51,429M
up 1.4% y/y
Next report
~ Jan 27
not announced yet
The quarter in brief
Total revenues rose 1.4% y/y to $51.43B with flat premiums and growth at CarelonRx; the benefit expense ratio improved 70 basis points to 90.6% and net investment income jumped to $1,037M from $625M; shareholders' net income rose 14.8% to $1,365M ($6.27 per diluted share vs $5.32).
Key growth driver: Net investment income less net losses on financial instruments (calculated) — the fastest-growing revenue line: $989, +59% y/y. · by the Q3 2026 report
How does Elevance Health make money?
Elevance Health brought in $51.4 billion of revenue in Q3 2026, up 1.4% year over year. The largest source was Premiums: $41.7 billion, or 81% of the total, followed by Product revenue ($6.45B, 13%) and Service fees ($2.28B, 4%); other lines add the remaining 2%. Net income for the quarter was $1.36 billion, up 14.8% year over year.
Revenue by source, Q3 2026
- Premiums$41.7B · 81% · −0.2%
- Product revenue$6.45B · 13% · +4.8%
- Service fees$2.28B · 4% · +6.8%
- Net investment income less net losses on financial instruments (calculated)$989M · 2% · +58.5%
Shares of $51.4B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
All figures in $M.
| Line item | Amount and change |
|---|---|
| Premiums | $41,704 · −0.2% |
| Product revenue | $6,454 · +4.8% |
| Service fees | $2,282 · +6.8% |
| Net investment income less net losses on financial instruments (calculated) | $989 · +58.5% |
| Total revenues | $51,429 · +1.4% |
| Benefit expense | $37,779 · −0.9% |
| Cost of products sold | $5,640 · +4.8% |
| Operating expense | $5,752 · +9.1% |
| Interest expense | $358 · +2.0% |
| Amortization of other intangible assets | $106 · −34.6% |
| Income before income tax expense | $1,794 · +27.6% · 3.5% margin |
| Income tax expense | $451 · +106% · 25.1% effective rate |
| Net loss (gain) attributable to noncontrolling interests | $22 · +1000% |
| Shareholders' net income | $1,365 · +14.8% · $6.27/sh · 2.7% margin |
Verdict: total revenues rose 1.4% y/y to $51.43B with flat premiums and growth at CarelonRx; the benefit expense ratio improved 70 basis points to 90.6% and net investment income jumped to $1,037M from $625M; shareholders' net income rose 14.8% to $1,365M ($6.27 per diluted share vs $5.32).
FY 2026 guidance raised: diluted EPS at least $22.00, adjusted diluted EPS (non-GAAP) at least $29.00, operating cash flow at least $6.5 billion; Q3 adjusted diluted EPS $6.99; $330 million of shares repurchased in the quarter and a $1.72 quarterly dividend paid.
Source and notation
Source: Elevance Health earnings release, 8-K EX-99 of 10/21/2026 (SEC EDGAR). Insurer layout: total revenues = premiums + net investment income + fees and other revenues + realized investment gains (losses), as reported; benefits, claims and expenses are deducted to reach pre-tax income. The income statement lines were taken from the release by hand; the program found every figure in the release text and checked the accounting identities and the chart balance; SEC XBRL for this quarter is not published yet, so the XBRL check is pending.
Open as an image: Elevance Health (ELV), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Elevance Health (ELV) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/elv. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/elv"><img src="https://whoreportstoday.com/t/elv/img/elevance-health-elv-earnings-sankey.png" alt="Elevance Health (ELV) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/elv">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/elv/img/elevance-health-elv-earnings-sankey.png
<a href="https://whoreportstoday.com/t/elv">Elevance Health (ELV) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Premiums were $41,704M vs $41,791M; product revenue rose to $6,454M from $6,159M and service fees to $2,282M from $2,137M.
- Operating expense rose 9.1% to $5,752M and the operating expense ratio was 11.4%.
- Medical membership was about 44.9 million at September 30, 2026, down 487 thousand year over year.
- Carelon operating revenue rose to $19.3 billion from $18.3 billion; Health Benefits operating gain fell to $0.4 billion from $0.6 billion.
- Income tax expense rose 105.9% to $451M; pre-tax income grew 27.6% to $1,794M.
- Diluted shares fell 2.7% to 217.6 million from 223.7 million.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
- Gail K. BoudreauxPresident and Chief Executive Officer [1]
- Mark B. KayeExecutive Vice President and Chief Financial Officer [2]
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Elevance Healthsince 2017President and Chief Executive Officer; Director
- GKB Global Health2015–2017Chief Executive Officer
- UnitedHealth Group2008–2015Executive Vice President
- UnitedHealthcare2008–2014
- Chief Executive Officer2011–2014
- President of the Commercial Business2008–2010
3 more
- Health Care Service Corporation2005–2008Executive Vice President of External Operations
- Blue Cross and Blue Shield of Illinois2002–2005President
- AetnaSenior Vice President, Group Insurance
Source: SEC EDGAR: 10-K annual report, 2026-02-06 · as of 10/21/2026
- Elevance Healthsince 2023
- Executive Vice President and Chief Financial Officersince 2023
- Chief Financial Officer Designate2023
- Moody's2018–2023
- Executive Vice President and Chief Financial Officer2021–2023
- Senior Vice President - Chief Financial Officer2018–2021
- MassMutual2016–2018Senior Vice President and Head of Financial Planning and Analysis
- MassMutual U.S.2015–2016Chief Financial Officer
3 more
- Voya Financial2011–2015Chief Financial Officer and Senior Vice President, Retirement Solutions
- ING U.S. and ING GroupSenior financial and risk reporting positions
- Credit Suisse First BostonInvestment Banking Division
Source: SEC EDGAR: 10-K annual report, 2026-02-06 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-10-21 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-10-21 · SEC EDGAR · 11/18/2026
Elevance Health, Inc. is an American health insurance company. · Text: Wikipedia, CC BY-SA 4.0, abridged
Prior to June 2022, Elevance Health was named Anthem, Inc. The company is the world's seventh largest healthcare company based on revenue. Its services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliated companies such as Anthem Blue Cross and Blue Shield, Anthem Blue Cross in California, Wellpoint, and Carelon. It is the largest for-profit managed health care company in the Blue Cross Blue Shield Association.
Company reports
Company guidance
Same quarter a year ago (ended December 31, 2025): revenue $49.7B, EPS (GAAP) $2.56
How we calculate
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
ELV earnings history: past report dates
| Oct 21, 2026 Wed | 6:01 ambefore market open | Sep 30, 2026 | $51.4B+1% y/y | $6.27+18% y/y |
| Jul 15, 2026 Wed | 6:01 ambefore market open | Jun 30, 2026 | $50.5B+1% y/y | $6.71−13% y/y |
| Apr 22, 2026 Wed | 6:02 ambefore market open | Mar 31, 2026 | $50.2B+3% y/y | $8.00−17% y/y |
| Jan 28, 2026 Wed | 6:03 ambefore market open | Dec 31, 2025 | ≈$49.7B+9% y/y | ≈$2.56+36% y/y |
| Oct 21, 2025 Tue | 6:01 ambefore market open | Sep 30, 2025 | $50.7B+12% y/y | $5.32+22% y/y |
| Jul 17, 2025 Thu | 6:03 ambefore market open | Jun 30, 2025 | $49.8B+13% y/y | $7.72−22% y/y |
| Apr 17, 2025 Thu | 10:24 amduring market hours | Mar 31, 2025 | $48.9B+15% y/y | $9.61+0% y/y |
| Jan 23, 2025 Thu | 6:03 ambefore market open | Dec 31, 2024 | ≈$45.4B+7% y/y | ≈$1.88−49% y/y |
| Oct 17, 2024 Thu | 6:02 ambefore market open | Sep 30, 2024 | $45.1B+5% y/y | $4.36−20% y/y |
| Jul 17, 2024 Wed | 6:09 ambefore market open | Jun 30, 2024 | $43.9B+0% y/y | $9.85+26% y/y |
| Apr 18, 2024 Thu | 6:07 ambefore market open | Mar 31, 2024 | $42.6B+1% y/y | $9.59+16% y/y |
| Jan 24, 2024 Wed | 6:04 ambefore market open | Dec 31, 2023 | ≈$42.6B+7% y/y | ≈$3.68+2% y/y |
| Oct 18, 2023 Wed | 6:05 ambefore market open | Sep 30, 2023 | $42.8B+7% y/y | $5.45−18% y/y |
| Jul 19, 2023 Wed | 6:04 ambefore market open | Jun 30, 2023 | $43.7B+13% y/y | $7.79+16% y/y |
| Apr 19, 2023 Wed | 6:05 ambefore market open | Mar 31, 2023 | $42.2B+11% y/y | $8.30+13% y/y |
Show all 15 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Elevance Health: 15-year financials
| 2025 | 199,125 | 7,199 | 5,662 | 3,174 | 1,529 |
| 2024 | 177,011 | 7,862 | 5,980 | 4,552 | 1,508 |
| 2023 | 171,340 | 8,499 | 5,987 | 6,765 | 1,395 |
| 2022 | 156,595 | 8,283 | 5,894 | 7,247 | 1,229 |
| 2021 | 138,639 | 7,559 | 6,158 | 7,277 | 1,104 |
| 2020 | 121,867 | 6,360 | 4,572 | 9,667 | 954 |
| 2019 | 104,213 | 5,999 | 4,807 | 4,984 | 818 |
| 2018 | 92,105 | 5,426 | 3,750 | 2,619 | 776 |
| 2017 | 90,040 | 4,175 | 3,843 | 3,394 | 705 |
| 2016 | 84,863 | 4,801 | 2,470 | 2,686 | 684 |
| 2015 | 79,157 | 4,753 | 2,560 | 3,574 | 657 |
| 2014 | 73,874 | 4,418 | 2,570 | 2,655 | 481 |
| 2013 | 71,024 | 4,001 | 2,490 | 2,406 | 448 |
| 2012 | 61,497 | 3,620 | 2,656 | 2,200 | 367 |
| 2011 | 60,711 | 3,782 | 2,647 | 2,855 | 358 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. Dividends paid and share buybacks are actual annual cash payments from the cash flow statement, shown as positive cash outflows. Payments to noncontrolling interests and share-compensation withholding taxes are excluded. New values require three checks against issuer documents; unreviewed data is a dash and confirmed absence of payment is 0. Buybacks appear only when at least one reviewed payment exists in fifteen years. Updated after annual filings and document review. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Elevance Health: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 121,494 | 43,882 | 32,046 | 9,491 | 63,001 | 41,035 |
| 2024 | 116,889 | 41,315 | 31,232 | 8,288 | 58,942 | 40,581 |
| 2023 | 108,928 | 39,306 | 25,120 | 6,526 | 60,029 | 41,791 |
| 2022 | 102,755 | 36,243 | 24,114 | 7,387 | 55,617 | 39,696 |
| 2021 | 97,456 | 36,095 | 23,031 | 4,880 | 51,122 | 34,885 |
| 2020 | 86,615 | 33,199 | 20,035 | 5,741 | 45,751 | 29,453 |
| 2019 | 77,453 | 31,728 | 20,085 | 4,937 | 39,033 | 23,532 |
| 2018 | 71,571 | 28,541 | 19,211 | 3,934 | 34,321 | 21,965 |
| 2017 | 70,540 | 26,503 | 19,932 | 3,609 | 36,263 | 23,356 |
| 2016 | 65,083 | 25,101 | 15,727 | 4,075 | 34,315 | 21,294 |
| 2015 | 61,718 | 23,045 | 15,865 | 2,113 | 30,862 | 19,093 |
| 2014 | 61,676 | 24,251 | 15,044 | 2,152 | 31,948 | 18,753 |
| 2013 | 59,575 | 24,765 | 14,492 | 1,582 | 29,746 | 16,352 |
| 2012 | 58,955 | 23,803 | 14,978 | 2,475 | 29,348 | 15,995 |
| 2011 | 52,163 | 23,288 | 9,840 | 2,202 | 27,097 | 15,899 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-30 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 7,512 | 4,206 | +3,306 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 1,083 | 1,140 | |
| · incl. stock-based comp (non-cash)share-based compensation | 210 | 246 | |
| Capexpurchases of property & equipment | −789 | −823 | +34 |
| Free cash flow ≈operating cash flow − capex | 6,723 | 3,383 | +3,340 |
| Investing activities, netcapex, acquisitions, securities | −3,470 | −1,808 | −1,662 |
| · incl. acquisitionsbusinesses net of cash acquired | 2 | 55 | −53 |
| Financing activities, netdebt, buybacks, dividends | −3,171 | −1,974 | −1,197 |
| · incl. buybacksrepurchases of common stock | −1,688 | −2,134 | +446 |
| · incl. dividends paid | −1,122 | −1,152 | +30 |
| FX effect on cash | −14 | 1 | −15 |
| Net change in cash | 857 | 425 | +432 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Bank or insurer: CAPEX and FCF do not apply to this business model — “—”.
Shareholders’ equity at Sep 30, 2026: $44.7B (35% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Feb 20262025 10-K cover: a single class — Common Stock $0.01 (NYSE: ELV). sec.gov ↗
- Feb 2026Diluted share count −11.7% over 2020–2025; buybacks of $2.6–2.9B in 2023–2025; SBC 0.14% of revenue (XBRL). data.sec.gov ↗
2 more facts and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Feb 2026Per-share dividend $3.80 (2020) → $5.92 (2023); a quarterly dividend of $1.72 was declared in February 2026. sec.gov ↗
- Feb 2026The Litigation and Regulatory Proceedings section of the 2025 10-K lists BCBS antitrust cases and a DOJ suit over Medicare risk adjustment; no settled shareholder disclosure suits or SEC cases. sec.gov ↗
Scoring: 2.0 with no deductions = 2.0 (single share class, shares −11.7% over 5 years, dividend rising, 2025 class action unresolved, no SEC cases)
- Share classes
- Single class of common stock (10-K cover: Common Stock, NYSE).
- Dilution
- Diluted shares −11.7% over 2020–2025 on buybacks of $1.9–2.9B a year; SBC 0.14% of revenue.
- Disclosure
- Full 10-K/10-Q reporting.
- Dividends
- Dividend raised every year: $3.80 (2020) → $5.92 (2023) → $1.72 quarterly in 2026.
- Lawsuits & regulators
- Class action Miller v. Elevance (S.D. Ind., May 2025) over Medicaid cost guidance — unresolved → no deduction; the 10-K's litigation is antitrust (BCBS) and False Claims Act (not about disclosure to investors); no SEC cases.
- Related parties
- No material related-party transactions in the 2026 proxy.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies with revenue growth 10 years in a row · S&P 500 companies that paid dividends 10 years without a gap · S&P 500 companies shrinking their share count
Elevance Health (ELV) earnings: FAQ
How does Elevance Health make money?
Elevance Health brought in $51.4 billion of revenue in Q3 2026, up 1.4% year over year. The largest source was Premiums: $41.7 billion, or 81% of the total, followed by Product revenue ($6.45B, 13%) and Service fees ($2.28B, 4%); other lines add the remaining 2%. Net income for the quarter was $1.36 billion, up 14.8% year over year.
When is ELV's next earnings date?
We have not yet seen an announcement of the date from Elevance Health (ELV). Based on last year's report on Jan 28, 2026, the next report is expected around Jan 27, 2027.
What time does ELV report earnings?
Elevance Health usually reports before market open: its latest results release was filed with the SEC at 6:01 am ET on Oct 21, 2026.
When did ELV last report earnings?
Elevance Health reported Q3 2026 results on Oct 21, 2026.
Where can I find Elevance Health's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to ELV's filings; this page breaks the latest report down in a Sankey chart.
What was ELV's net income in Q3 2026?
Elevance Health reported net income of $1,365M for Q3 2026 (+14.8% year over year), under US GAAP.
Does Elevance Health pay dividends?
Yes. In 2025, Elevance Health paid $1,529M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.
How has Elevance Health's revenue changed since 2011?
Per its 10-K filings, revenue grew 3.3x: $60,711M in 2011 and $199,125M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: EW · Q2 2026 · GEHC · Q3 2026 · GILD · Q3 2026 · HCA · Q3 2026 · HSIC · Q3 2026 · HUM · Q2 2026 · IDXX · Q3 2026 · ILMN · Q3 2026 · INCY · Q2 2026 · IQV · Q3 2026 · all reports